JFJosephine Fisker-Andersen

Josephine Fisker-Andersen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects

Research Interests


Josephine Fisker-Andersen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exogenous Glucagon Acutely Reduces Insulin Clearance in Healthy Humans

    by Nina Lerberg Hansen, Sophie Betty Brock Johnsen, Elvar Már Sturlaugsson Jóhönnuson, Josephine Fisker-Andersen, Caroline Hansen, Anton Born, Marie Winther-Sørensen, Sasha Alexandra Sampson Kjeldsen, Nicolai J Wewer Albrechtsen

    Context: Glucagon is secreted from pancreatic alpha-cells in response to hypoglycemia and protein intake and acts as a counterregulatory hormone to insulin by stimulating hepatic glucose production, thereby maintaining euglycemia. However, some studies suggest that glucagon regulates insulin availability by stimulating insulin secretion and reducing insulin clearance. Objective: To investigate the glucose-independent effect of glucagon on insulin secretion and insulin clearance in healthy individuals. Methods: A total of 15 healthy participants were included in this single arm, crossover clinical study with two study days. The participants received a four-hour intravenous infusion of glucagon (10 ng × kg(bodyweight)-1×min-1) on the first study day and a four-hour intravenous infusion of glucose (to match the glucose excursions from the glucagon infusion) on the second study day. The primary endpoint was insulin secretion (c-peptide). Results: Overall glucose exposure did not differ significantly between study days (P = 0.0717); however, peak plasma glucose was significantly higher on the glucose clamp day (8.1 (7.5-8.7) vs 7.7 (7.0-8.3) mmol/L, P = 0.0027), reflecting incomplete glucose matching. Steady state concentrations of glucagon were 124 (110-137) pmol/L on the glucagon study day and 3 (2-4) pmol/L on the glucose clamp study day. There was no statistically significant difference in insulin secretion between study days (P = 0.1179), whereas insulin clearance (post hoc analysis) was significantly reduced during glucagon infusion at both hyper- and euglycemia (P = 0.0003). Conclusions: Exogenous glucagon rapidly reduces insulin clearance without a statistically significant effect on insulin secretion, suggesting that glucagon affects hepatic insulin removal in healthy individuals.

  • Glucagon may be extracted across the liver by a glucagon receptor-dependent mechanism, and this is impaired in an animal model of fatty liver disease

    by Cecilie C. N. Huynh, Josephine Fisker-Andersen, Richard G. Kay, Alexander Jakobsen, Bolette Hartmann, Jens J. Holst, Lise Lotte Gluud, Fiona Gribble, Caroline Hansen, Marie Winther-Sørensen, et al.

    We identify the liver as an active glucagon‐clearing organ: ∼20% of portal glucagon is extracted under physiological conditions via glucagon receptor-dependent uptake, not enzymatic cleavage. DPP-4 and neprilysin inhibition does not alter hepatic glucagon disappearance, and mass spectrometry confirms glucagon remains largely intact. Strikingly, diet-induced hepatic steatosis nearly abolishes glucagon extraction, coinciding with reduced hepatic GCGR expression, suggesting impaired receptor-mediated clearance may contribute to hyperglucagonemia in MASLD.